Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03070301 · ClinicalTrials.gov registry record · Phase 2
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03070301: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03070301 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03070301, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.
Interventions
- DRUG everolimus
- DRUG LEE011
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2024-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03070301
The ClinicalTrials.gov registry entry for NCT03070301 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which everolimus is the first listed.
NCT03070301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03070301 about?
NCT03070301 is a clinical study titled "A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors". The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.
What is the current status of trial NCT03070301?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2017-02-27. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT03070301?
The interventions under investigation include: everolimus (DRUG), LEE011 (DRUG).
Who is sponsoring clinical trial NCT03070301?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.